Rising Cases Of Peripheral Artery Disease Fueling The Growth Of The Market Due To Increasing Prevalence And Risk Factors: Key Factor Driving The Growth In The Intermittent Claudication Market

The Intermittent Claudication Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Intermittent Claudication Market Size During the Forecast Period?
The market for intermittent claudication has seen robust growth in the past few years. The market size is estimated to increase from $12.81 billion in 2024 to $13.64 billion in 2025, with a compound annual growth rate (CAGR) of 6.5%. Factors contributing to the historic period's growth include an upsurge in peripheral artery disease, heightened awareness of vascular diseases, an expanding aging population, higher diagnosis rates, and an escalation in healthcare expenses.

In the coming years, the market size for intermittent claudication is projected to experience robust growth, hitting $17.39 billion in 2029 with a 6.2% compound annual growth rate (CAGR). This expansion during the forecast period is likely due to several factors such as the escalating rates of diabetes, the rising prevalence of obesity, a growth in cardiovascular diseases, an increase in alcohol and tobacco use, and a boost in healthcare expenditure. Significant trends anticipated for this forecast period encompass breakthroughs in pad diagnostics, the introduction of wearable devices, personalized medicine integration, a pivot towards drug-eluting stents, and new developments in stem cell therapy.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22021

What Are the High-Growth Segments in the Intermittent Claudication Market?
The intermittent claudication market covered in this report is segmented -

1) By Type: Medication Therapies, Revascularization
2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration
3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline
2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp

What Key Drivers Are Expected to Influence Future Intermittent Claudication Market Growth?
The escalation in occurrences of peripheral artery disease (PAD) is anticipated to drive the expansion of the intermittent claudication market. PAD refers to a circulatory issue where constricted arteries diminish blood flow to extremities, leading to pain, loss of sensation, and complications. The rise in PAD cases is linked to factors like an aging population, diabetes, tobacco use, high blood pressure, obesity, and inactive lifestyles. PAD inflicts intermittent claudication by curtailing blood flow to the leg muscles when exercising, causing pain and muscle cramps due to lack of oxygen. For instance, a report in June 2023 from the American Heart Association Journals, a peer-reviewed scientific journal based in the U.S., estimated that PAD affects between 7-12 million people in the U.S. and 200 million worldwide. Hence, the escalating incidences of PAD are fuelling the expansion of the intermittent claudication market.

Which Companies Hold the Largest Share Across Different Intermittent Claudication Market Segments?
Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, Pharmacompass.

What Trends Are Driving Growth in The Intermittent Claudication Market?
Leading corporations in the intermittent claudication sector are emphasizing on innovative medicine therapies, for example, RIPK1 inhibitors, to augment treatment results for patients grappling with peripheral artery disease (PAD) associated with intermittent claudication. Through this, the aim is to ameliorate blood circulation, decrease inflammation, and ward off disease advancement. RIPK1 inhibitors are specialized drugs that hinder RIPK1 kinase activity, thereby lessening inflammation and cellular death. To illustrate, GenFleet, a biotechnology firm situated in China, earned approval from the US Food and Drug Administration (FDA) in August 2022 to undertake a Phase II clinical trial for GFH312, a novel treatment for peripheral artery disease (PAD) coupled with intermittent claudication (IC). This randomized, double-blinded, placebo-controlled research will take place in 15 research institutions. GFH312 is a RIPK1 inhibitor that has demonstrated potential in preclinical trials by repressing the inflammatory reaction in animal models.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report

What Are the Emerging Geographies for The Intermittent Claudication Market Growth?
North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Intermittent Claudication Market?
2. What is the CAGR expected in the Intermittent Claudication Market?
3. What Are the Key Innovations Transforming the Intermittent Claudication Industry?
4. Which Region Is Leading the Intermittent Claudication Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.